Retail Offer opens and dispatch of Offer Booklet
Released
Released
Announcement PDF
ASX Announcement
26 October 2023
Retail Entitlement Offer opens and dispatch of Retail Offer Booklet
to Eligible Retail Shareholders
Not for release to US wire services or distribution in the United States
Microba Life Sciences Limited (ASX:MAP) ("Microba" or "the Company") on Thursday, 19 October 2023, announced the
launch of a A$20.0 million pro rata accelerated non-renounceable entitlement offer (Entitlement Offer) of new fully paid
ordinary shares (New Shares) at an offer price of A$0.23 per New Share (Offer Price).
Funds raised under the Entitlement Offer will be used by Microba to fund the acquisition of UK based Invivo Clinical Limited
(Acquisition). Refer to the ASX Announcement of Thursday, 19 October 2023 for further detail on the Acquisition.
The Entitlement Offer is comprised of a fully underwritten offer of 1 New Share for every 4 ordinary shares to raise gross
proceeds of A$20.0 million.
The Retail Entitlement Offer opens today, Thursday, 26 October 2023. The Retail Entitlement Offer is expected to close at
5.00pm (Sydney time) on Thursday, 16 November 2023 (unless extended).
The Entitlement Offer consists of an entitlement offer to eligible institutional shareholders (Institutional Entitlement Offer),
and an entitlement offer to eligible retail shareholders (Retail Entitlement Offer).
The Entitlement Offer is being made without a prospectus or disclosure document in accordance with section 708AA of the
Corporations Act 2001 (Cth) (Corporations Act) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument
2016/84.
Attached is a copy of the offer booklet for the Retail Entitlement Offer (Retail Offer Booklet) which will be made
available to eligible retail shareholders either by email (if they have elected to receive electronic communications only),
online or by post together with a personalised entitlement and acceptance form (Entitlement and Acceptance Form). A
copy of the Retail Offer Booklet is also accessible at https://www2.asx.com.au.
Also attached is a sample of a letter that will be made available to Microba shareholders who are eligible to participate,
notifying them of the Retail Entitlement Offer.
The Retail Offer Booklet and the Entitlement and Acceptance Form contain important information about the Retail
Entitlement Offer, including how eligible shareholders can apply to participate in the Retail Entitlement Offer.
If you have any queries about the Entitlement Offer, please contact the Share Registry, Automic on 1300 288 664 (within
Australia) or +61 2 9698 5414 (outside Australia) between 8.30am and 8.00pm (Sydney time) on Monday to Friday during
the offer period.
This announcement has been authorised for release by the Board.
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
Investor / Media Relations
E: investor@microba.com
W: https://ir.microba.com/
Join our Investor Mailing List
ASX Announcement
26 October 2023
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions.
Disclaimer
Forward looking statements
This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend",
"believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify
forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also
forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on
assumptions and contingencies that are subject to change without notice and involve known and unknown risks and
uncertainties and other factors that are beyond the control of Microba, its directors and management. This includes
statements about market and industry trends, which are based on interpretations of current market conditions.
Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee
of future performance. Actual results, performance or achievements may differ materially from those expressed or implied
in such statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Microba’s business strategies. The success of any of those strategies will be realised in the period for
which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue
reliance on forward-looking statements and except as required by law or regulation, none of Microba, its representatives or
advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or
implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or
statements in relation to future matters contained in this document. The forward-looking statements are based on
information available to Microba as at the date of this document. Except as required by law or regulation (including the ASX
Listing Rules), none of Microba, its representatives or advisers undertakes any obligation to provide any additional or updated
information whether as a result of a change in expectations or assumptions, new information, future events or results or
otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forwardlooking statements.
Not an offer in the United States
This document has been prepared for publication in Australia and may not be released to US wire services or distributed in
the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the
United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document
have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “US Securities Act”) or the
securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may
not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction
not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other
jurisdiction of the United States
For more information visit: www.microba.com
Microba encourages all current investors to go paperless by registering their details with the designated registry service
provider, Automic Group.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
26 October 2023
Not for release to US wire services or distribution in the United States
Dear Shareholder,
NOTIFICATION TO ELIGIBLE RETAIL SHAREHOLDERS
On Thursday 19 October 2023, Microba Life Sciences Limited (Microba) announced the launch of a A$20.0 million pro rata
accelerated non-renounceable entitlement offer (Entitlement Offer) of new fully paid ordinary shares (New Shares) at an
offer price of A$0.23 per New Share (Offer Price).
Funds raised under the Entitlement Offer will be used by Microba to fund the acquisition of UK based Invivo Clinical Limited
(Acquisition). Refer to the ASX Announcement of Thursday, 19 October 2023 for further detail on the Acquisition.
The Entitlement Offer is comprised of a fully underwritten offer of 1 New Share for every 4 ordinary shares to raise gross
proceeds of A$20.0 million.
It is expected that approximately 87 million New Shares will be issued under the Entitlement Offer (comprising
approximately 25% of Microba's existing issued capital). The Entitlement Offer is fully underwritten by Bell Potter Securities
Limited and Morgans Corporate Limited (Underwriters, or the Joint Lead Managers).
The Entitlement Offer is being made without a prospectus or disclosure document in accordance with section 708AA of the
Corporations Act 2001 (Cth) (Corporations Act) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument
2016/84.
The Entitlement Offer consists of an entitlement offer to eligible institutional shareholders (Institutional Entitlement Offer),
and an entitlement offer to eligible retail shareholders (Retail Entitlement Offer).
The Institutional Entitlement Offer was conducted between Thursday, 19 October 2023 and Friday, 20 October 2023, with
the results announced on the ASX on Monday, 23 October 2023. The Institutional Entitlement Offer has raised
approximately A$12.3 million (before costs). The Retail Entitlement Offer may raise approximately a further A$7.7 million
for Microba.
New Shares will rank equally in all respects with Microba's existing ordinary shares. If an eligible shareholder's entitlement
results in a fraction of a new share, the shareholder's entitlement will be rounded up to the nearest whole number.
On Thursday, 26 October 2023, an offer booklet for the Retail Entitlement Offer (Retail Offer Booklet) will be lodged with
the ASX and made available to eligible retail shareholders with a registered address in Australia or New Zealand as at
7.00pm (Sydney time) on Monday, 23 October 2023 (Record Date), not being US persons or acting for the account or
benefit of persons in the US (Eligible Retail Shareholders).
You are an Eligible Retail Shareholder as at the Record Date
As an Eligible Retail Shareholder, you are offered an allocation of 1 New Share for every 4 Microba shares that you held as
at the Record Date (Entitlement) if (and only if) application monies are received via BPAY® or EFT prior to the closing date of
the Retail Entitlement Offer in accordance with the Retail Offer Booklet and your personalised Entitlement and Acceptance
Form (Entitlement and Acceptance Form).
Eligible Retail Shareholders can choose to take up all, or part or none of their Entitlement under the Retail Entitlement Offer.
In addition to each Eligible Retail Shareholder’s Entitlement under the Retail Entitlement Offer, Eligible Retail Shareholders
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
will be offered the opportunity to apply for additional New Shares under a “top-up” facility (Oversubscription Facility). Under
the Oversubscription Facility, Eligible Retail Shareholders may apply for New Shares in excess of their Entitlement (Additional
Shares) which represents the lower of that number which represents 100% of their Entitlement or $50,000 worth of New
Shares (Additional Share Cap).
The shortfall, if any, will then be placed in accordance with the terms of the Underwriting Agreement.1
The Offer Price of A$0.23 per New Share represents a:
•
•
23.8% discount to the theoretical ex-rights price (TERP)2 of A$0.302; and
28.1% discount to the last close price of Microba shares of A$0.32 on Wednesday, 18 October 2023.
How to obtain a copy of the Retail Offer Booklet and your personalised Entitlement and Acceptance Form
The Entitlement Offer is now open and closes at 5.00pm (Sydney time) on Thursday, 16 November 2023 (unless extended).
A copy of your personalised Entitlement and Acceptance Form is enclosed. You must read the Retail Offer Booklet before
accepting the Entitlement Offer or making an application for Additional Shares.
You may obtain a copy of the Retail Offer Booklet and your personalised Entitlement and Acceptance Form online by
completing one of the below three processes.
I don’t have an online account with
Automic – but wish to register for
one
I don’t have an online account with
Automic – but want to use Automic for this
Offer only
Go to: https://investor.automic.com.au
Go to:
https://investor.automic.com.au/#/signup
Go to:
https://investor.automic.com.au/#/loginsah
Select: “Existing Users Sign In”
Once you have successfully signed in,
click on “Documents and Statements”
Select: Microba Life Sciences Limited
from the dropdown list in the ISSUER
field.
Select: Microba Life Sciences Limited from the
dropdown list in the ISSUER field.
Download the Offer Booklet and
personalised Entitlement and
Acceptance Form
Enter you holder number SRN
/ HIN (from your latest Holding
Statement)
Enter you holder number SRN
/ HIN (from your latest Holding Statement)
Enter Postcode (Aust only) or Country
of Residence (if not Australia)
Enter Postcode (Aust only) or Country of
Residence (if not Australia)
Tick box “I am not a robot”, then Next.
Tick box “I am not a robot”, then Access
Complete prompts
Once you have successfully signed in,
click on “Documents and Statements”
Once you have successfully signed in, click on
“Documents and Statements”
I already have an online account
with the Automic Share registry
Do not return your Entitlement and
Acceptance Form
Download the Offer Booklet and
personalised Entitlement and
Acceptance Form
Download the Offer Booklet and personalised
Entitlement and Acceptance Form
Do not return your Entitlement and
Acceptance Form
Do not return your Entitlement and
Acceptance Form
1
Refer to the Retail Offer Booklet for details of the material terms of the Underwriting Agreement.
Theoretical ex-rights price (TERP) is the theoretical price that Microba shares should trade at immediately after the ex-rights date for the Entitlement
Offer. It is a theoretical calculation only and the actual price at which Microba shares trade immediately after the Entitlement Offer will depend on many
factors and may not be equal to TERP. TERP is calculated by reference to Microba's closing share price of A$0.32 on Wednesday, 18 October 2023 and
includes New Shares issued under the Entitlement Offer.
2
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
Microba encourages you to access the Retail Offer Booklet online.
The Entitlement Offer is scheduled to close at 5.00pm (Sydney time) on Thursday, 16 November 2023 (unless extended).
Payment must be received before this time.
You should read the Retail Offer Booklet carefully and in its entirety before deciding whether to participate in the Retail
Entitlement Offer.
Actions required by Eligible Retail Shareholders
Your Entitlement is shown on the personalised Entitlement and Acceptance Form that accompanies the Retail Offer Booklet
which can be accessed as detailed above.
The choices available to Eligible Retail Shareholders are described in the Retail Offer Booklet. In summary, Eligible Retail
Shareholders may:
(a)
take up their Entitlement in full, or take up all of their Entitlement and apply for Additional Shares up to the
Additional Share Cap;
(b)
take up part of their Entitlement and allow the balance to lapse; or
(c)
take no action and allow all of their Entitlement to lapse.
For further detail, see section 4 of the Retail Offer Booklet.
If you wish to take up all or part of your Entitlement (and, if applicable, apply for Additional Shares), please pay your
application monies via BPAY® by following the instructions set out in your personalised Entitlement and Acceptance Form by
no later than 5.00pm (Sydney time) on Thursday, 16 November 2023.
Questions
If you have any queries about the Entitlement Offer, please contact the Share Registry, Automic on 1300 288 664 (within
Australia) or +61 2 9698 5414 (outside Australia) between 8.30am and 8:00pm (Sydney time) on Monday to Friday during the
offer period.
On behalf of the Board, I invite you to consider this investment opportunity and thank you for your continued support.
Yours sincerely
Pasquale Rombola
Chair, Microba Life Sciences Limited
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions.
Disclaimer
Forward looking statements
This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend",
"believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and
financial position and performance are also forward-looking statements. Forward-looking statements, opinions and
estimates provided in this document are based on assumptions and contingencies that are subject to change without notice
and involve known and unknown risks and uncertainties and other factors that are beyond the control of Microba, its
directors and management. This includes statements about market and industry trends, which are based on interpretations
of current market conditions.
Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee
of future performance. Actual results, performance or achievements may differ materially from those expressed or implied
in such statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Microba’s business strategies. The success of any of those strategies will be realised in the period for
which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue
reliance on forward-looking statements and except as required by law or regulation, none of Microba, its representatives or
advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or
implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or
statements in relation to future matters contained in this document. The forward-looking statements are based on
information available to Microba as at the date of this document. Except as required by law or regulation (including the ASX
Listing Rules), none of Microba, its representatives or advisers undertakes any obligation to provide any additional or updated
information whether as a result of a change in expectations or assumptions, new information, future events or results or
otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forwardlooking statements.
Not an offer in the United States
This document has been prepared for publication in Australia and may not be released to US wire services or distributed in
the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the
United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document
have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “US Securities Act”) or the
securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may
not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction
not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other
jurisdiction of the United States
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
Microba Life Sciences Limited
ACN 617 096 652
Retail Offer Booklet
For a fully underwritten accelerated non-renounceable pro-rata entitlement offer of 1 New
Share for every 4 Existing Shares held by Eligible Retail Shareholders at the Record Date
(i.e., 7.00pm (Sydney time) on Monday, 23 October 2023) at an issue price of A$0.23 per
New Share to raise A$20.0 million.
The retail entitlement offer opens on Thursday, 26 October 2023 and closes at 5.00pm
(Sydney time) on Thursday, 16 November 2023. Valid acceptances must be received before
that time.
The Entitlement Offer is fully underwritten by Bell Potter Securities Limited and Morgans
Corporate Limited.
Please read the instructions in this Retail Offer Booklet and the accompanying Entitlement
and Acceptance Form regarding the acceptance of your entitlement under the Entitlement
Offer.
This is an important document that requires your immediate attention and should be read in
its entirety. If you are in doubt about what to do, you should consult your stockbroker,
accountant, lawyer or other professional adviser.
This Retail Offer Booklet is not a prospectus. It does not contain all of the information that
an investor would find in a prospectus and has not been lodged with ASIC.
This Retail Offer Booklet may not be released to US wire services or distributed in the United
States.
1
Important notice
offering of the New Shares, in any jurisdiction other than Australia
and New Zealand.
This Retail Offer Booklet has been issued by Microba Life Sciences
Limited ACN 617 096 652 (Microba).
The distribution of this Retail Offer Booklet (including an electronic
copy) outside Australia and New Zealand, is restricted by law. If you
come into possession of the information in this Retail Offer Booklet,
you should observe such restrictions. Any non-compliance with these
restrictions may contravene applicable securities laws.
This Retail Offer Booklet is dated 26 October 2023 and relates to the
Retail Entitlement Offer, which is part of the Entitlement Offer by
Microba. Capitalised terms in this section have the meaning given to
them in this Retail Offer Booklet.
The Retail Entitlement Offer is made pursuant to section 708AA of
the Corporations Act 2001 (Cth) (Corporations Act) (as notionally
modified by ASIC Corporations (Non-Traditional Rights Issues)
Instrument 2016/84 and ASIC Corporations (Disregarding Technical
Relief) Instrument 2016/73) for the offer of New Shares without
disclosure to investors under a prospectus.
This Retail Offer Booklet is not a prospectus or a product disclosure
statement under the Corporations Act and has not been lodged with
ASIC. This Retail Offer Booklet does not contain all of the information
which would be required to be disclosed in a prospectus or product
disclosure statement. As a result, it is important for you to read and
understand the publicly available information in relation to Microba
and the Entitlement Offer (e.g. the information available on Microba's
website at https://ir.microba.com/asx-announcements/ or on ASX’s
website at www.asx.com.au) prior to deciding whether to accept your
Entitlement and apply for New Shares. The information in this Retail
Offer Booklet does not constitute financial product advice and does
not take into account your investment objectives, financial situation
or particular needs.
Please contact your professional adviser or Microba’s Share
Registry, Automic, on 1300 288 664 (within Australia) or +61 2
9698 5414 (outside Australia) between 8.30am and 8:00pm
(Sydney time) on Monday to Friday if you have any questions.
This Retail Offer Booklet should be read in its entirety (including the
accompanying Entitlement and Acceptance Form) before you decide
to participate in the Retail Entitlement Offer. In particular, the Investor
Presentation in Section 10 of this Retail Offer Booklet details
important factors and risks that could affect the financial and
operating performance of Microba. Please refer to the ‘Key risks’
section of the Investor Presentation for details. When making an
investment decision in connection with the Retail Entitlement Offer, it
is essential that you consider these risk factors carefully in light of
your individual personal circumstances, including financial and
taxation issues (some of which have been outlined in Section 7 of this
Retail Offer Booklet).
In addition to reading this Retail Offer Booklet in conjunction with
Microba's other periodic and continuous disclosure announcements
including the Investor Presentation and Microba's announcements to
ASX and on its website, you should conduct your own independent
review, investigations and analysis of Microba and the New Shares
and obtain any professional advice you require to evaluate the merits
and risks of an investment in Microba before making any investment
decision.
New Zealand
The New Shares are not being offered to the public within New
Zealand other than to existing Shareholders of Microba with
registered addresses in New Zealand to whom the offer of these
securities is being made in reliance on the Financial Markets Conduct
(Incidental Offers) Exemption Notice 2021.
This Retail Offer Booklet has been prepared in compliance with
Australian law and has not been registered, filed with or approved by
any New Zealand regulatory authority under the Financial Markets
Conduct Act 2013. This Retail Offer Booklet is not a product
disclosure statement under New Zealand law and is not required to,
and may not, contain all the information that a product disclosure
statement under New Zealand law is required to contain.
United States
None of the information in this Retail Offer Booklet or the
accompanying Entitlement and Acceptance Form constitutes an offer
to sell, or the solicitation of an offer to buy, any securities in the United
States. Neither this Retail Offer Booklet (or any part of it), the
accompanying ASX Announcements and Investor Presentation nor
the accompanying Entitlement and Acceptance Form may be
distributed, directly or indirectly, to persons in the United States.
The New Shares have not been, and will not be, registered under the
U.S. Securities Act of 1933, as amended (U.S. Securities Act) or the
securities laws of any state or other jurisdiction of the United States.
The Entitlements may not be taken up by persons in the United
States, and the New Shares may not be offered or sold, directly or
indirectly, in the United States, except in transactions exempt from,
or not subject to, the registration requirements of the U.S. Securities
Act and applicable securities laws of any state or other jurisdiction of
the United States.
Definitions
Defined terms used in this Retail Offer Booklet are contained in
Section 8.
Taxation
There will be tax implications associated with participating in the
Retail Entitlement Offer and receiving New Shares. Section 7
provides for a general guide to the Australian income tax, goods and
services tax and stamp duty implications of the Retail Entitlement
Offer for Australian Eligible Retail Shareholders.
The guide does not take account of the individual circumstances of
particular Eligible Retail Shareholders and does not constitute tax
advice. Microba recommends that you consult your professional tax
adviser in connection with the Retail Entitlement Offer.
By paying for your New Shares through BPAY® in accordance with
the instructions on the Entitlement and Acceptance Form, you
acknowledge that you have read this Retail Offer Booklet and you
have acted in accordance with and agree to the terms of the Retail
Entitlement Offer detailed in this Retail Offer Booklet.
Privacy
Entitlement and Acceptance Form
By paying for your New Shares through BPAY® in accordance with
the instructions on the Entitlement and Acceptance Form, you will be
providing personal information to Microba (directly or through the
Share Registry). Microba collects, holds and will use that information
to assess your Application. Microba collects your personal
information to process and administer your shareholding in Microba
and to provide related services to you. Microba may disclose your
personal information for purposes related to your shareholding in
Microba, including to the Share Registry, Microba's related bodies
corporate, agents, contractors and third-party service providers,
including mailing houses and professional advisers, and to ASX and
regulatory bodies. You can obtain access to personal information
that Microba holds about you. To make a request for access to your
personal information held by (or on behalf of) Microba, please contact
Microba through the Share Registry.
The Entitlement and Acceptance Form accompanying this Retail
Offer Booklet is important. To participate in the Entitlement Offer, you
must complete the Entitlement and Acceptance Form and pay the
Application Money before 5.00 pm (Sydney time) on Thursday, 16
November 2023.
Please refer to the instructions in Section 4 regarding the acceptance
of your Entitlement.
No overseas offering
This Retail Offer Booklet and the accompanying Entitlement and
Acceptance Form do not constitute an offer or invitation in any place
in which, or to any person to whom, it would
Share your feedback
Discover